

## DAFTAR RUJUKAN

- Abbas, A.B., Lichtman, A.H. 2009. Ch.2 Innate Immunity : In Saunders (Elsevier) *Basic Immunology*. Functions and disorders of the immune system (3rd ed.)
- Adamczak, M., Wiecedilcek, A., Funahashi, T., Chudek, J., Kokot, F., Matsuzawa, Y., 2003. Decreased plasma adiponectin concentration in patients with essential hypertension. *Am J Hypertens*. 16:72–75.
- Aronson, D., Eliot, R. 2002, Eliot How hyperglycemia promotes atherosclerosis: molecular Mechanisms. *Cardiovasc Diabetol*. 1-10.
- Bautista, L.E., Vera, L.M., Arenas, I.A., Gamarra, G. 2005. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. *J Hum Hypertens*. 19(2):149-54.
- Bevan, P. 2001. Insulin signalling. *J. Cell Sci*. 114:1429-1430
- Boger, R.H., Sydow, K., Borlak, J. 2000. LDL Cholesterol Upregulates Synthesis of Asymmetrical Dimethylarginine in Human Endothelial Cells Involvement of S-Adenosylmethionine-Dependent Methyl transferases. *Circ Res*. 87: 99-105
- Ceriello, A., Motz, E. 2004. Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited. *Arterioscler Thromb Vasc Biol*. 24:816-823
- Celoria, B.M., Genelhu, V.A., Pimentel Duarte, S.F., Delfraro, P.A., Francischetti, E.A. 2010. Hypoadiponectinemia is associated with prehypertension in obese individuals of multiethnic origin. *Clin Cardiol*. 33(6):E61-5.
- Chen, H., Montagnani, M. 2003. Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial Cells. *J Biol Chem*. 278 : 45, 45021–45026.
- Chobanian, A.V., Bakris, G.I., Black, H.R. 2003. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*, 289:2560-2572.

- Chrysohoou, C., Pitsavos, C., Panagiotakos, D.B., Skoumas, J., Stefanadis, C. 2004, Association between prehypertension status and inflammatory markers related to atherosclerotic disease : The ATTICA Study. *Am J Hypertens*; 17:568-73.
- Dar MS, Pandith AA, Sameer AS, Sultan M, Yousuf A and Mudassar S. 2010. hs-CRP: A Potential Marker for Hypertension in Kashmiri Population. *Indian J Clin Biochem.* 25: 208-212.
- Devaraj. S., Swarbrick, M.M., Singh, U., Adams-Huet, B., Havel, P.J., Jialal, I. 2008. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. *Am J Clin Pathol.* 129(5):815-22.
- Dzau, V. 2005. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. *J Hypertens Suppl.* 23(1):S9-17.
- Ferrero-Miliani, L., Nielsen, O.H., Andersen, P.S., Girardin, S.E. 2007. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. *Clin Exp Immunol.* ;147(2):227-35.
- Fong, P., Stafforini, D.M., Brown, N.J., Pretorius, M. 2010. Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism. *Free Radic Biol Med.*49(2):301-5.
- Fukui, T., Ishizaka, N., Rajagopalan, S., Laursen, J.B., Capers, Q., Taylor, W.R., et al. 1997. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. *Circ Res.*;80:45-51.
- Furuhansi, M., Ura, N., Higashiura, K. 2003. Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension. *Hypertension.* 42:76-81.
- Geisler, T., Bhatt, D.L. 2004. The role of inflammation in atherothrombosis: current and future strategies of medical treatment. *Med Sci Monit.* 10(12):RA 308-16.
- Govindarajan, G., Sowers, J., Stump, C.S., 2006. Hypertension and Diabetes Mellitus Bussiness Briefing. *Cardiology.* .....1-7
- Gokce, N. 2004. L-arginine and hypertension. *J Nutr.* 134(10 Suppl):2807S-2811

- Gupta, P., Nagaraju, S.P., Gupta, A., Chikkalingaiah, K.B. 2012. Prehypertension, - time to act. *Saudi J Kidney Dis Transpl.* 23(2):223-33.
- Hivert, M.F., Sullivan, L.M., Fox, C.S., Nathan, D.M. 2008. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. *J Clin Endocrinol Metab.* 93(8):3165-72
- Heitzer, T., Wenzel, U., Hink, U., Krollner, D., Skatchkov, M., Stahl, R.A. 1999. Increased NAD(P)H oxidase-mediated superoxide production in reno. ascular hypertension: evidence for an involvement of protein kinase C. *Kidney Int* 55: 252–260.
- Jonk, A.M., Houben, A.J., de Jongh, R.T., Serné, E.H., Schaper, N.C., Stehouwer, C.D. 2007. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. *Physiology (Bethesda).* ;22:252-60.
- Kawamoto, R., Kohara, K., Tabara, Y. 2010. Insulin Resistance and Prevalence of Prehypertension and Hypertension among Community-Dwelling Person. *J Atheroscler Throm,* 17:148-155
- Kon, K., Hwan, S. 2005. Inflammatory Markers and The Metabolic Syndrome : Insight From Therapeutic Interventions, *Elsevier*
- Knobler, H., Abbasi, F., Lamendola, C., Reaven, G.M. 2011. Insulin resistance and cardiovascular disease risk factors in subjects with prehypertension. *Diab Vasc Dis Res.* 8(1):43-6.
- Landmesser, U., Hornig, B., Drexler, H. 2004. Endothelial Function A Critical Determinant in Atherosclerosis. *Circulation.*, 109 suppl II:II-27–II-33.
- Lee, R., Margaritis, M., Channon, K.M., Antoniades, C. 2012. Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations. *Curr Med Chem.* 19, 2504-2520.
- Lerman, L.O., Nath, K.A., Rodriguez-Portel, M., Krier, J.D., Schwartz, R.S. 2001. Increased oxidative stress in experimental renovascular hypertension. *Hypertension.* 37(2 Part 2):541-6.
- Lundberg, J.O. 2006. Nitric oxide metabolites and cardiovascular disease markers, mediators, or both?. *J Am Coll Cardiol.* 7;47(3):580-1.

- Mainous, A.R., Everett, J.D., Liszka, H., King, D.E. 2004. Prehypertension and mortality in a nationally representative cohort. *Am J Cardiol.* 94(12): p. 1496-500
- Mancia. G., Backer. G., Dominizak.A., et al. 2007. Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), *Eur Heart J.* 28 :1462–1536.
- Matthews, D.R., Hosker, J.P., Rudenski, A.S. 1985. Homeostasis model assesment : insulin resistance and  $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 28: 412-419.
- Mulvihill, N.T., Boccalatte, M., Foley, J.B. 2002. Inflammatory markers as predictors of clinical outcome in acute coronary syndromes. *Minerva Cardioangiol.* 50(6):653-9.
- Ouchi, N., Kihara, S., Funahashi, T., Nakamura, T. 2003. Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue. *Circulation.* 107:671-674.
- Oruz A, Uzunlulu M, Yorulmaz M, et al, 2002, Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus, *Anadolu Kardiyol Derg* ; 7: 383-7
- Ouedraogo R, Wu X, Xu SQ, et al, 2006, Adiponectin Suppression of High-Glucose–Induced Reactive Oxygen Species in Vascular Endothelial Cells Evidence for Involvement of a cAMP Signaling Pathway *Diabetes* 55:1840–1846.
- Paulo, S. 2005. The “common soil” theory: coronary disease, diabetes and inflammation. *Med J.* 123(5):207-8.
- Perticone, F., Maio, R., Sciacqua, A., 2008. Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential. *Diabetes.* 57:167–171.
- Raitakari, O.T., Celermajer, D.S. 2000. Testing for endothelial dysfunction. *Ann Med.* 32(5):293-304.
- Saad, M.F., Rewers, M., Selby, J., Howard, G. 2004, Insulin resistance and hypertension. The Insulin Resistance Atherosclerosis Study, *Hypertension* ; 43:1324–31.

- Sabanayagam, C., Shankar, A., Lee, J., Wong, T.Y. 2011. Serum C-reactive protein level and prehypertension in two Asian populations, *Am J Hypertens.* 24(2): 225–233.
- Sedeek, M., Llinas, M.T., Drummond, H., Fortepiani, L. 2003. Role of Reactive Oxygen Species in Endothelin-Induced Hypertension. *Hypertension.* 42: 806-810.
- Sherwood, E., Taiver-Kinsky, T. 2004. Mechanism of inflammatory response, *Best Pract Res Clin Anaesthesiol.* 18(3 ):385–405.
- Sibal, L., Agarwal, S.C., Home, P.D., Boger, R.H., 2010. The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. *Curr. Cardiol. Rev.* 6,:82-90.
- Stühlinger, M.C. , Abbasi, F., Chu, J.W., Lamendola, C., et al. 2002. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. *JAMA.*20;287(11):1420-6.
- Suzuki, H., Eguchi, S. 2006. Adiponectin versus angiotensin II: Key pathological role of their misbalance. *Kidney Int.* 70: 1678–1679.
- Sung, S.H., Chuang, S.Y., Sheu, W.H., Lee, W.J., Chou, P., Chen, C.H.2008. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity. *Hypertens Res.* 31(4):633-40.
- Taniyama, Y., Hitomi, H., Shah, A.R., Alexander, W., Griending, K.K. 2005. Mechanisms of Reactive Oxygen Species–Dependent Downregulation of Insulin Receptor Substrate-1 by Angiotensin II. *Arterioscler Thromb Vasc Biol.* 25:1142-1147
- Thuillez, C., Richard, V. 2005. Targeting endothelial dysfunction in hypertensive subjects. *J Hum Hypertens.*19: S21–S25.
- Urukawa, H., Katsuki, A., Sumida, Y. 2003. Oxidative Stress Is Associated with Adiposity and Insulin Resistance in Men. *J Clin Endocrinol Metab.* 88: 4673–4676.
- Vallance, P., Leone, A.M., Calver, A., Collier, J., Moncada, S. 1992. Endogenous dimethylarginine as an inhibitor of nitric oxide synthase. *J Cardiovasc Pharmacol.* 20 (12): S60-2.
- Yu, Q., Gao, F., Ma, X.L. 2011. Insulin says NO to cardiovascular disease. *Cardiovasc Res.* 15;89(3):516-24.

Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, Howard BV, 2006, Prehypertension, Diabetes and Cardiovascular Disease Risk in a Population – Based Sample: The Strong Heart Study, *Hypertension* :47:410-414).